![]() |
JOURNAL TOOLS |
Opzioni di pubblicazione |
eTOC |
Per abbonarsi |
Sottometti un articolo |
Segnala alla tua biblioteca |
ARTICLE TOOLS |
Estratti |
Permessi |
Share |


I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEWS
International Angiology 2011 August;30(4):299-320
Copyright © 2011 EDIZIONI MINERVA MEDICA
lingua: Inglese
Anticoagulant drugs: what is new?
Kei A. 1, Florentin M. 1, 2, Elisaf M. S. 1, Liberopoulos E. N. 1 ✉
1 Department of Internal Medicine, University of Ioannina Medical School, Ioannina, Greece 2 Department of Clinical Biochemistry (Vascular Prevention Clinics), Royal Free campus, University College London Medical School, University College London (UCL), London UK
Heparins and vitamin K antagonists have been the cornerstones of anticoagulation treatment for several decades. Despite their effectiveness, these agents have limitations which can include food and drug interactions and the need for monitoring. It follows that there is a need for new anticoagulants. There are numerous promising agents at various stages of evaluation. Those in the most advanced stages of development are the oral factor Xa and the thrombin inhibitors, which are the focus of this review.